Company intelligence / Profile preview
Pelage Pharmaceuticals
Los Angeles, California, USApelagepharma.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Pelage’s lead candidate PP405 is a novel topical small molecule that reactivates dormant hair follicle stem cells by inhibiting the mitochondrial pyruvate carrier. Phase 1 clinical data demonstrated safety and statistically significant activation of hair follicle stem cells after one week of treatment. The company has advanced to Phase 2a trials enrolling diverse participants with androgenetic alopecia to evaluate safety and preliminary efficacy[1][6][9][10].
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small molecule therapeutics (topical application)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed; licensed IP from University of California/UCLA Technology Development Group.
Beyond the preview
Go deeper on Pelage Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pelage Pharmaceuticals.